Skip to main content

Pfizer Expands Voluntary Recall to Include All Lots of CHANTIX® Tablets Due to N-Nitroso Varenicline Content

By kbm0423 on

Pfizer is voluntarily recalling all lots of Chantix 0.5 mg and 1 mg Tablets to the consumer level due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the FDA interim acceptable intake limit. 

As alternative suppliers have been approved in the United States, Pfizer is undertaking this precautionary measure.

Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate risk to patients taking this medication. 

Chantix

The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline.

According to the FDA, nitrosamines are common in water and foods, including cured and grilled meats, dairy products and vegetables. Everyone is exposed to some level of nitrosamines. 

These impurities may increase cancer risk if people are exposed to them above acceptable levels over long periods of time.

According to the CDC, Chantix is a treatment to help patients quit smoking and is intended for short-term use. People who smoke cigarettes are 15 to 30 times more likely to get lung cancer than people who do not smoke.

According to the Department of Health and Human Services, smoking is also associated with many other cancers and cardiovascular disease and lung disease.

CHANTIX has a safety profile that has been established over 15 years of marketing authorization and through a robust clinical program. Pfizer believes the benefit/risk profile of CHANTIX remains positive. 

Chantix

Patients currently taking Chantix should consult with their healthcare provider about alternative treatment options. To date, Pfizer has not received reports of adverse events assessed to be related to this recall.

The products were distributed nationwide to Wholesalers and Distributors in the United States, US Virgin Islands and Puerto Rico from May 2019 to September 2021.

Pfizer emphasizes patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer has notified their direct consignees by letter to arrange for the return of any recalled product.

Wholesalers and Distributors with an existing inventory of Chantix tablets should stop use and distribution and quarantine the product immediately.

Chantix

If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you. Please conduct a sub-recall to those accounts and communicate this recall information immediately. 

Please request they immediately cease distribution of the product and promptly contact Stericycle at 888-276-6166 (Mon.-Fri. 8:00 a.m. - 5:00 p.m. ET) to obtain a Business Reply Form (BRF) to initiate the return process.

If you received a free product through the Pfizer Patient Assistance Program (PAP) or the Pfizer Institutional Patient Assistance Program (IPAP), please check your stock immediately. 

If you have any of the products in inventory, please follow the instructions above for returning the product to Stericycle Inc. Additionally, if you are aware of any patients to whom you dispensed the products and who still may have the product in their possession, please ask them to return the product to you and then follow the instructions above for returning the product to Stericycle Inc. 

For any questions related to Pfizer PAP or Pfizer IPAP products, please contact 833-203-2776 (Mon.-Fri. 8:00 a.m. – 6:00 p.m. ET).

As communicated by FDA, there is no immediate risk to patients taking Chantix. Patients taking this product should consult with their health care provider to determine if alternative treatments are available. 

Patients with Chantix Tablets should contact Stericycle Inc. at 888-276-6166 (Mon.-Fri. 8:00 a.m. - 5:00 p.m. ET) for instructions on how to return their product and obtain reimbursement for their cost.

Contact

Adverse reactions or quality problems experienced with this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

Complete and submit the report Online https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda

Regular Mail or Fax: Download form https://www.fda.gov/safety/medical-product-safety-information/medwatch-forms-fda-safety-reporting or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

This recall is being executed with the knowledge of the U.S. Food and Drug Administration.

Recalled Product Details PRODUCT: Chantix Tablets, 0.5 mg NDC: 0069-0468-56 SIZE: Bottle of 56 Tablets EXPIRATION DATE: January 2022 - May 2023 LOT NUMBERS:

Recall Lot Numbers

PRODUCT: Chantix Tablets, 1 mg NDC: 0069-0469-56 SIZE: Bottle of 56 Tablets EXPIRATION DATE: September 2021 – December 2023 LOT NUMBERS:

Recall Lot Numbers

PRODUCT: Chantix Tablets, 1 mg NDC: 0069-0469-03 SIZE: Carton containing 4 blister packs of 14 tablets each EXPIRATION DATE: September 2021 – June 2023 LOT NUMBERS:

Recall Lot Numbers

PRODUCT: Chantix Tablets, 0.5/1 mg NDC: 0069-0471-03 SIZE: Carton containing one blister pack of 11 0.5 mg tablets and one blister pack containing 42 1 mg tablets EXPIRATION DATE: August 2021 – January 2023 LOT NUMBERS:

Recall Lot Numbers